Float Short %

7.65

Margin Of Safety %

-30

Put/Call OI Ratio

0.4

EPS Next Q Diff

-0.7

EPS Last/This Y

-3.43

EPS This/Next Y

-1.07

Price

67.06

Target Price

82.27

Analyst Recom

1.79

Performance Q

78.18

Relative Volume

0.73

Beta

1.22

Ticker: ARWR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	ARWR	70.2	0.26	0.28	34002
2025-12-29	ARWR	69.62	0.26	0.01	34711
2025-12-30	ARWR	67.21	0.25	0.12	35586
2025-12-31	ARWR	66.39	0.26	0.65	37065
2026-01-02	ARWR	67.75	0.26	0.54	37500
2026-01-05	ARWR	63.88	0.27	0.48	40320
2026-01-06	ARWR	70.82	0.37	0.69	48468
2026-01-07	ARWR	65.68	0.38	3.02	46063
2026-01-08	ARWR	64.96	0.48	1.53	50234
2026-01-09	ARWR	64.58	0.45	1.73	50389
2026-01-12	ARWR	65.91	0.50	0.26	54301
2026-01-13	ARWR	65.57	0.49	0.53	55151
2026-01-14	ARWR	65.9	0.49	1.34	55355
2026-01-15	ARWR	66.3	0.50	1.13	55778
2026-01-16	ARWR	63.87	0.50	0.66	55824
2026-01-20	ARWR	65.27	0.41	0.63	36085
2026-01-21	ARWR	67.58	0.42	0.04	36485
2026-01-22	ARWR	69.56	0.40	0.12	37378
2026-01-23	ARWR	67.03	0.40	0.24	38058
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	ARWR	70.14	93.1	-309.8	-3.16
2025-12-29	ARWR	69.62	93.1	-308.4	-3.16
2025-12-30	ARWR	67.25	93.1	-303.6	-3.16
2025-12-31	ARWR	66.38	93.1	-307.4	-3.16
2026-01-02	ARWR	67.77	93.1	-313.5	-3.16
2026-01-05	ARWR	63.88	93.1	-299.4	-3.16
2026-01-06	ARWR	70.76	93.1	-329.2	-3.16
2026-01-07	ARWR	65.69	93.1	-296.8	-3.16
2026-01-08	ARWR	64.95	93.1	-307.7	-3.31
2026-01-09	ARWR	64.58	93.1	-306.6	-3.31
2026-01-12	ARWR	65.93	77.3	-313.5	-3.53
2026-01-13	ARWR	65.55	77.3	-308.7	-3.46
2026-01-14	ARWR	65.91	77.3	-310.7	-3.44
2026-01-15	ARWR	66.26	77.3	-311.9	-3.44
2026-01-16	ARWR	63.86	77.3	-303.2	-3.44
2026-01-20	ARWR	65.28	77.3	-313.8	-3.44
2026-01-21	ARWR	67.59	77.3	-316.1	-3.44
2026-01-22	ARWR	69.58	77.3	-315.0	-3.44
2026-01-23	ARWR	67.06	77.3	-303.2	-3.44
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	ARWR	-3.91	5.71	8.14
2025-12-29	ARWR	-3.91	5.71	8.13
2025-12-30	ARWR	-3.96	5.71	8.13
2025-12-31	ARWR	-4.51	5.71	8.13
2026-01-02	ARWR	-4.51	5.71	8.13
2026-01-05	ARWR	-4.51	5.72	8.13
2026-01-06	ARWR	-5.46	5.72	8.13
2026-01-07	ARWR	-5.46	5.72	8.13
2026-01-08	ARWR	-5.46	5.72	8.13
2026-01-09	ARWR	-5.46	5.72	8.13
2026-01-12	ARWR	-5.42	5.53	8.13
2026-01-13	ARWR	-5.39	5.53	7.65
2026-01-14	ARWR	-5.39	5.53	7.65
2026-01-15	ARWR	-5.39	5.53	7.65
2026-01-16	ARWR	-5.39	5.53	7.65
2026-01-20	ARWR	-5.39	5.42	7.65
2026-01-21	ARWR	-5.39	5.42	7.65
2026-01-22	ARWR	-5.39	5.42	7.65
2026-01-23	ARWR	-5.39	5.42	7.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.18

Avg. EPS Est. Current Quarter

-0.1

Avg. EPS Est. Next Quarter

-0.88

Insider Transactions

-5.39

Institutional Transactions

5.42

Beta

1.22

Average Sales Estimate Current Quarter

244

Average Sales Estimate Next Quarter

Fair Value

47.26

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

28.4

Max Drawdown 5-Year %

-89

Target Price

82.27

P/E

Forward P/E

PEG

P/S

10.98

P/B

19.52

P/Free Cash Flow

58.07

EPS

-0.07

Average EPS Est. Cur. Y

-3.44

EPS Next Y. (Est.)

-4.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-0.2

Relative Volume

0.73

Return on Equity vs Sector %

-27.6

Return on Equity vs Industry %

-11.6

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.27

EBIT Estimation

-303.2

Arrowhead Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 711

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today

news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance

stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market

stock prices ARWR premarket after hours

ticker ARWR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ARWR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y